secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001437749-26-002876
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azenta Q1 revenue $149M flat; GAAP EPS -$0.11; non-GAAP EPS $0.09; reaffirms FY2026 guidance
--------------------------------------------------------------------------------

- Revenue $149M (+1% YoY); organic revenue -1%. Sample Mgmt $81M flat; Multiomics $67M (+1%).
- GAAP diluted EPS from continuing ops -$0.11 (vs -$0.16); total diluted EPS -$0.34. Non-GAAP EPS $0.09 (vs $0.12).
- Gross margin 42.9% (down 380bps) on lost leverage & rework costs; operating margin -4.9%.
- Adjusted EBITDA $13M, margin 8.5% (down 230bps). Board authorized $250M share repurchase program through Dec 2028.
- Definitive agreement to sell B Medical Systems for $63M; close expected by March 31, 2026. FY2026 guidance reaffirmed: organic rev growth 3-5%, ~300bps adj EBITDA margin expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000143774926002876/0001437749-26-002876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000143774926002876/azta20251120_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-002876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer